<DOC>
	<DOCNO>NCT02810444</DOCNO>
	<brief_summary>This Phase III clinical study test efficacy , safety pharmacokinetics BT595 treat patient Primary Immunodeficiency ( PID )</brief_summary>
	<brief_title>Study Investigate Efficacy , Safety Pharmacokinetics BT595 Subjects With PID</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Main Written inform consent/assent obtain subjects/subjects ' parent ( ) legally acceptable representative indicating understand purpose procedure require study willing participate . Male female , age 2 75 year . Diagnosis PID impair antibody production , i.e . : Diagnosis common variable immunodeficiency ( CVID ) define European Society Immunodeficiencies ( ESID ) /Pan American Group Immunodeficiency ( PAGID ) diagnostic criterion . Or X link agammaglobulinemia ( XLA ) define ESID/PAGID diagnostic criterion . Established replacement therapy intravenous immunoglobulin ( IVIg ) reference preparation previous 6 month , include documentation immunoglobulin G ( IgG ) trough level . Established replacement therapy single IVIg reference preparation least 3 month prior treatment start BT595 3 4 week schedule constant IVIg dose change ±20 % mean dose , regular dosage interval , least 1 IgG trough level ≥5 g/L previous 3 month . Main Known intolerance immunoglobulin comparable substance ( e.g. , vaccination reaction ) . Known intolerance protein human origin know allergic reaction component study product . Acquired medical condition know cause secondary immune deficiency , chronic lymphatic leukemia , lymphoma , multiple myeloma , well protein lose enteropathy hypoalbuminemia . Recent febrile illness precludes delays participation . Active infection receive antibiotic therapy treatment infection time screen . Note : subject deem screen failure due nonserious active infection require antibiotic therapy , subject may rescreened initial screening . Therapy systemic steroid immunosuppressant drug time enrollment ( current daily use corticosteroid , i.e. , &gt; 10 mg prednisone equivalent/day &gt; 30 day . Intermittent corticosteroid use study allowable , medically necessary ) . History thrombotic event ( include myocardial infarction , cerebral vascular accident [ include stroke ] , pulmonary embolism , deep vein thrombosis ) within 6 month treatment start BT595 presence significant risk factor thrombotic event . Therapy live attenuate virus vaccine within 3 month start study . Selective , absolute immunoglobulin A ( IgA ) deficiency know antibody IgA .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>